China's Biocytogen gets $78m Series D
Chinese contract research organization (CRO) Biocytogen has raised a RMB543 million ($78 million) Series D round led by China Life Insurance and SDIC Venture Capital, a VC arm of the State Development & Investment Corporation (SDIC).
Existing investors CMB International – an investment arm of China Merchants Bank – Materia Medica Capital, and 3E Bioventures also participated in the funding round, according to a release. All three...
More on Greater China
Latest News
Asia IPOs gone cold: India edition
A compilation of India-based IPOs - some of them private equity-backed - that have been withdrawn or appear to have fallen behind schedule
China LiDAR specialist Hesai aims for US IPO
Hesai Technology, a China-based developer of sensors used in autonomous driving, is targeting a US listing. Its investors include Lightspeed China Partners, Baidu, Bosch, and Xiaomi.
Indonesia fintech start-up iSeller gets $12m
Indonesia financial technology start-up iSeller, which helps businesses to digitise sales and operations, has raised USD 12m in Series B funding led by Intudo Ventures.
Hillhouse-backed China pet services business seeks US listing
New Ruipeng Pet Group, a China-based pet care services platform that counts Hillhouse Capital as a significant shareholder, has filed for an IPO in the US.